The chief scientific officer of the American health care company said that Johnson & Johnson is on its way to launch an anti-Corona virus vaccine in March, and expects to obtain clear data about its effectiveness by the end of this month or early February, according to the British Daily Mail newspaper.
Dr. Paul Stoffels, chief scientific officer of the American health care company at Johnson Company, confirmed that the company expects to achieve its stated goal of providing one billion doses of its vaccine by the end of this year as the company increases production.
Stoffels added that it is too early to say how many doses will be available in March, assuming the company receives emergency clearance from the US Food and Drug Administration.
The New York Times reported earlier, Johnson was experiencing manufacturing delays that would reduce the number of doses available initially.
He stressed: We aim to obtain a billion doses in 2021, and if the vaccine is taken with a single dose, then this means that a billion people will receive the vaccination. And the newspaper said, "Johnson & Johnson": Johnson & Johnson vaccine is produced in the United States, Europe, South Africa and India with the help of Contracting manufacturers to build capacity.
He said: "It is still a few weeks early to give the final figures for what we can launch in the first two months."
Expect high efficiency.
Moncef Al-Salawi, senior advisor for the US Warp Speed vaccine development program, said that the vaccine can show efficacy at 80% or more.
This would be less than the approximately 95% effectiveness achieved in Pfizer already authorized vaccine trials with BioNTech and Moderna, but well above the approval standard of 50% set by the regulators, and it has the distinction of being a single-shot vaccine, which means it can Protect more people faster, and without cold storage requirements for other vaccines.
Stovills added, that the company has set a target for effectiveness at 60%, explaining that the vaccine will be much higher than 60%, adding that "the goal is to reach the highest levels, and we hope to get close to the effectiveness of Moderna and Pfizer."
Interim results from the company's Phase 1/2 study, published Wednesday in the New England Journal of Medicine, helped boost this confidence.
The study showed that 90% of 805 volunteers between the ages of 18 and 55 years developed protective antibodies 29 days after a single dose, and these bodies increased to 100% on day 57, the study is continuing, but protection has lasted 71 days so far, and data will also be available. Similar in participants over the age of 65 in late January.
The study also evaluated the effect of two doses of the vaccine 56 days apart, and found that the booster vaccine more than doubled the level in neutralizing antibodies against the Coronavirus.
Comments
Post a Comment